Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ramanathan

Showing results (221-230 of 302) with videos related to

Pageof 31
Sort By:
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Oncotarget|August 29, 2015
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancerMichael T Barrett, Karen S Anderson, Elizabeth Lenkiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Cancer|June 15, 2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancerAmanda C Ashley, Daniel J Sargent, Steven R Alberts, et al.
Clinical Colorectal Cancer|August 5, 2011
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancerBenedito A Carneiro, Ramesh K Ramanathan, Marwan G Fakih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Pageof 31

Showing results (221-230 of 302) with videos related to

Sort By:
Pageof 31
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Oncotarget|August 29, 2015
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancerMichael T Barrett, Karen S Anderson, Elizabeth Lenkiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Molecular Cancer Therapeutics|March 5, 2020
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid TumorsJohn H Strickler, Patricia LoRusso, Ravi Salgia, et al.
Cancer|June 15, 2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancerAmanda C Ashley, Daniel J Sargent, Steven R Alberts, et al.
Clinical Colorectal Cancer|August 5, 2011
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancerBenedito A Carneiro, Ramesh K Ramanathan, Marwan G Fakih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Pageof 31